Mebendazole Reprograms Oncogenic Networks Across Multiple Cancer Types
Researchers found that mebendazole at 0.7 µM reprogrammed oncogenic and tumor-suppressor networks across eight cancer cell lines, suppressing ENOX2 and MMP2 while activating RASSF1A by over 200-fold.
By Sanare Lab · August 6, 2026 · 5 min read
Key Takeaway
A 2026 study published in PLOS ONE by researchers from Jordan and the UAE found that mebendazole — a widely available antiparasitic drug — reprogrammed oncogenic (cancer-promoting) and tumor-suppressor networks across eight different cancer cell lines at a low concentration of 0.7 µM. The drug suppressed ENOX2 and MMP2 (proteins that drive cancer invasion and metastasis) while activating tumor suppressors including RASSF1A (which increased more than 200-fold in one model) and WFDC10A (which increased more than 40-fold). These are preclinical cell-culture findings; mebendazole is not approved for cancer treatment.
Drug repurposing — finding new therapeutic uses for existing, well-characterized medications — offers a faster and more cost-effective path to cancer treatment than developing entirely new drugs. Mebendazole, an antiparasitic benzimidazole drug used for decades to treat intestinal worm infections, has attracted growing scientific interest for its anticancer properties, particularly its ability to disrupt microtubule dynamics and interfere with cancer cell division.
A study published March 26, 2026, in PLOS ONE by Aqel RS, Ismail AS, El-Tanani M, and Satyam SM from Al-Ahliyya Amman University (Jordan) and RAK Medical and Health Sciences University (UAE) took a multi-cancer approach, profiling mebendazole's effects on oncogenic and tumor-suppressor gene networks across eight human cancer cell lines.
Table of Contents
- Study Design and Methods
- Key Findings
- Key Molecular Targets Explained
- Limitations and Context
- Frequently Asked Questions
- Shop Sanare Lab
- References
Study Design and Methods
The researchers profiled eight human cancer cell lines using quantitative RT-PCR (qRT-PCR) and western blotting to measure gene and protein expression. The cell lines included:
- Breast cancer: MCF7 (ER-positive) and MDA-MB-231 (triple-negative, aggressive)
- Colorectal cancer: HT29
- Pancreatic cancer: PANC1
- Lung cancer cell line
- Hepatocellular carcinoma (liver cancer): HEPG2
- Leukemia: K562
- Endothelial cells (vascular model)
Expression was assessed under basal conditions and following mebendazole exposure at 0.7 µM — a relatively low concentration. The study focused on five key molecular targets: ENOX2, MMP2, RASSF1A, WFDC10A, and METTL7A.
Key Findings
| Target Gene/Protein | Role in Cancer | Effect of Mebendazole | Cell Line(s) |
|---|---|---|---|
| ENOX2 | Oncogene (promotes cancer growth) | Significantly downregulated | HEPG2 (p<0.01), K562 (p<0.05) |
| MMP2 | Promotes invasion and metastasis | Suppressed (anti-invasive effect) | MDA-MB-231 (p<0.05), MCF7 (p<0.01) |
| RASSF1A | Tumor suppressor (often silenced in cancer) | Increased >200-fold | Endothelial cells (p<0.01); also HEPG2, HT29 |
| WFDC10A | Tumor suppressor | Elevated >40-fold | MDA-MB-231 (p<0.001) |
| METTL7A | Regulatory (context-dependent) | Endothelial enrichment; heterogeneous tumor regulation | Multiple lines |
The authors conclude that ENOX2-MMP2 signaling is a functional driver of invasion and metastasis, and that mebendazole reprograms these oncogenic-tumor suppressor networks in a cell-type-specific manner.
Key Molecular Targets Explained
ENOX2 (ecto-NADH oxidase disulfide-thiol exchanger 2) is a cell-surface enzyme overexpressed in many cancer types. It plays a role in cancer cell growth and has been proposed as a cancer biomarker. Mebendazole's ability to downregulate ENOX2 in liver cancer (HEPG2) and leukemia (K562) cells is a novel finding.
MMP2 (matrix metalloproteinase-2) is an enzyme that degrades the extracellular matrix — the structural scaffolding surrounding cells — enabling cancer cells to invade surrounding tissue and spread to distant organs (metastasize). Suppression of MMP2 by mebendazole in aggressive breast cancer cells (MDA-MB-231) and MCF7 cells suggests an anti-invasive effect.
RASSF1A is a well-characterized tumor suppressor gene that is frequently silenced by methylation in many cancers. Its dramatic upregulation (more than 200-fold) in endothelial cells following mebendazole treatment is a striking finding, though the clinical significance of this specific effect requires further investigation.
Limitations and Context
This is an in vitro (cell culture) study. The dramatic fold-changes observed (e.g., 200-fold RASSF1A increase) are laboratory measurements in specific cell lines and do not directly translate to clinical outcomes. The study used a single mebendazole concentration (0.7 µM) and did not assess dose-response relationships. No animal models or human clinical data are presented. Mebendazole is not approved for cancer treatment, and its use for this purpose should only be considered within a supervised clinical trial.
For background, see our guide to how fenbendazole compares with mebendazole.
Estimate a weight-based regimen with our protocol calculator.
Frequently Asked Questions
What is mebendazole and how does it relate to fenbendazole?
Mebendazole is an antiparasitic drug in the benzimidazole family — the same drug class as fenbendazole and albendazole. All three share a similar mechanism: they disrupt microtubules, the structural scaffolding that cells use to divide. Mebendazole is approved for human use as an antiparasitic in many countries but is not approved for cancer treatment anywhere.
What does it mean that mebendazole "reprogrammed" oncogenic networks?
The study found that mebendazole simultaneously reduced the activity of cancer-promoting genes (oncogenes like ENOX2 and MMP2) while increasing the activity of cancer-suppressing genes (tumor suppressors like RASSF1A and WFDC10A). This dual action — turning down the accelerator and turning up the brakes on cancer growth — is what the authors describe as "reprogramming" the oncogenic network.
Why was the study conducted across multiple cancer types?
The researchers used eight different cancer cell lines — including breast, colorectal, pancreatic, lung, liver, and leukemia — to assess whether mebendazole's effects were specific to one cancer type or broader. The multi-cancer approach helps identify which molecular targets are consistently affected across cancer types and which effects are cancer-specific, providing a more comprehensive picture of the drug's potential.
Can mebendazole be used to treat cancer now?
No. Mebendazole is not approved for cancer treatment. This study is preclinical research conducted in cell cultures. While the findings are scientifically interesting, they do not establish clinical efficacy or safety for cancer treatment in humans. Patients should not use mebendazole for cancer outside of a supervised clinical trial and should always consult a qualified oncologist.
Scientists tested mebendazole — a common antiparasitic drug in the same family as fenbendazole — on eight different types of cancer cells. At a low dose, the drug simultaneously switched off proteins that help cancer spread (like MMP2, which breaks down tissue barriers to allow invasion) and switched on proteins that normally suppress cancer growth (like RASSF1A, which increased more than 200 times in one model). This dual action across multiple cancer types suggests mebendazole may have broad anticancer potential. However, this is early-stage laboratory research; mebendazole is not approved for cancer treatment and has not been tested in human cancer patients for this purpose.
Shop Sanare Lab
Lab-tested fenbendazole products from the same benzimidazole drug family studied in this research. Links are provided for convenience — always review the label and consult a professional before use.
180 capsules — 99% purity, laboratory tested. Fenbendazole is a benzimidazole in the same drug family as mebendazole studied here.
Higher-dose fenbendazole capsules, laboratory tested
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
1. Aqel RS, Ismail AS, El-Tanani M, Satyam SM. Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A. PLoS One. 2026 Mar 26;21(3):e0345701. doi: 10.1371/journal.pone.0345701. PMCID: PMC13020803. PubMed PMID: 41886499
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.